Pan-PPAR agonist chiglitazar in patients with at-risk MASH and type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Background Chiglitazar, a pan-PPAR agonist approved for type 2 diabetes mellitus (T2DM) in China, has shown promise in improving hepatic metabolism. However, its efficacy in patients with at-risk MASH and T2DM remains unknown. We conducted this phase 2 trial to evaluate the efficacy and safety of chiglitazar in this population. Methods In this phase 2 multicenter, randomized, double-blind, placebo-controlled study, prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2200064367), conducted in Shanghai, China, from Oct 21, 2022, to May 31, 2024, patients with at-risk MASH and T2DM were randomized 2:1 to chiglitazar 48 mg daily or placebo for 24 weeks. Randomization was performed centrally using a computer-generated sequence via an Interactive Web Response System, and participants, care providers, and outcome assessors were blinded. Primary endpoint was the MASH improvement rate, defined as a ≥0.22 decrease in FibroScan-AST (FAST) score, a validated non-invasive surrogate threshold previously associated with histological benefit, rather than a direct histological measure. Secondary endpoints included liver enzymes, metabolic parameters and safety. Serum lipidomics and logistic LASSO regression were used to explore lipid associations with MASH improvement. Findings In total, 60 patients were randomized (chiglitazar: n=40; placebo: n=20). The FAST score-based MASH improvement rate was significantly higher with chiglitazar (67.5% [27/40]) than with placebo (30.0% [6/20]); unadjusted odds ratio 4.85, 95% CI 1.52–15.50, p = 0.006; adjusted OR 5.44, 95% CI 1.43–20.68, p = 0.013. Chiglitazar significantly reduced liver enzymes vs. placebo at week 24 (median change: ALT −47.0 vs. −23.0 U/L, p = 0.021; AST −24.0 vs. −12.1 U/L, p = 0.011; GGT: −30.0 vs. −11.0 U/L, p = 0.002) and improved insulin resistance (HOMA-IR: −3.3 vs. −1.0, p = 0.024). Adverse events occurred in 8/40 (20.0%) chiglitazar-treated and 3/20 (15.0%) placebo-treated patients; all were mild, and no serious adverse events occurred in either group. Exploratory analyses suggest that chiglitazar-induced lipidomic remodeling was associated with MASH improvement, Cer(d18:1/25:0) and GlcCer(d16:1/18:0) as key lipids of interest. Interpretation Chiglitazar 48 mg was effective and well-tolerated for treating MASH in Chinese patients with T2DM. Its therapeutic benefit may be partly associated with serum lipidome remodeling, warranting validation in future large-scale phase 3 trials. Funding This work was supported by the Shanghai Municipal Key Discipline (2024ZDXK0016) and The Key discipline project of Shanghai Pudong New Area Health Commission (PWZxk2026-01).

Authors

Institutions

Publication Details

Journal
EClinicalMedicine
Published
2026-11-19
DOI
https://doi.org/10.1016/j.eclinm.2026.104340
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pan-PPAR agonist chiglitazar in patients with at-risk MASH and type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Zhe Huang, Shufei Zang, Yun Gao, Yue Li et al.
EClinicalMedicine
Liver Disease Diagnosis and Treatment
article

Pan-PPAR agonist chiglitazar in patients with at-risk MASH and type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Zhe Huang, Shufei Zang, Yun Gao, Yue Li, Zhoujunhao Zhou, Rui Zhang, Jun Liu, Wang Fan, Ruixiao Shi, Ling Guo, Li Sheng, Tiange Sun, Zhiyan Yu, Yueyue Wu, Chaoyun Shen, Kai Wang, Hongxiang Zhao
article en

Abstract

Background Chiglitazar, a pan-PPAR agonist approved for type 2 diabetes mellitus (T2DM) in China, has shown promise in improving hepatic metabolism. However, its efficacy in patients with at-risk MASH and T2DM remains unknown. We conducted this phase 2 trial to evaluate the efficacy and safety of chiglitazar in this population. Methods In this phase 2 multicenter, randomized, double-blind, placebo-controlled study, prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2200064367), conducted in Shanghai, China, from Oct 21, 2022, to May 31, 2024, patients with at-risk MASH and T2DM were randomized 2:1 to chiglitazar 48 mg daily or placebo for 24 weeks. Randomization was performed centrally using a computer-generated sequence via an Interactive Web Response System, and participants, care providers, and outcome assessors were blinded. Primary endpoint was the MASH improvement rate, defined as a ≥0.22 decrease in FibroScan-AST (FAST) score, a validated non-invasive surrogate threshold previously associated with histological benefit, rather than a direct histological measure. Secondary endpoints included liver enzymes, metabolic parameters and safety. Serum lipidomics and logistic LASSO regression were used to explore lipid associations with MASH improvement. Findings In total, 60 patients were randomized (chiglitazar: n=40; placebo: n=20). The FAST score-based MASH improvement rate was significantly higher with chiglitazar (67.5% [27/40]) than with placebo (30.0% [6/20]); unadjusted odds ratio 4.85, 95% CI 1.52–15.50, p = 0.006; adjusted OR 5.44, 95% CI 1.43–20.68, p = 0.013. Chiglitazar significantly reduced liver enzymes vs. placebo at week 24 (median change: ALT −47.0 vs. −23.0 U/L, p = 0.021; AST −24.0 vs. −12.1 U/L, p = 0.011; GGT: −30.0 vs. −11.0 U/L, p = 0.002) and improved insulin resistance (HOMA-IR: −3.3 vs. −1.0, p = 0.024). Adverse events occurred in 8/40 (20.0%) chiglitazar-treated and 3/20 (15.0%) placebo-treated patients; all were mild, and no serious adverse events occurred in either group. Exploratory analyses suggest that chiglitazar-induced lipidomic remodeling was associated with MASH improvement, Cer(d18:1/25:0) and GlcCer(d16:1/18:0) as key lipids of interest. Interpretation Chiglitazar 48 mg was effective and well-tolerated for treating MASH in Chinese patients with T2DM. Its therapeutic benefit may be partly associated with serum lipidome remodeling, warranting validation in future large-scale phase 3 trials. Funding This work was supported by the Shanghai Municipal Key Discipline (2024ZDXK0016) and The Key discipline project of Shanghai Pudong New Area Health Commission (PWZxk2026-01).

EClinicalMedicineVol. 102
Shanghai Jiao Tong University (CN), Fudan University (CN), Shanghai University of Medicine and Health Sciences (CN), First Affiliated Hospital Zhejiang University (CN), Shenzhen Chipscreen Biosciences Co. (CN)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon